Protalix BioTherapeutics 경영진
경영진 기준 점검 4/4
Protalix BioTherapeutics CEO는 Dror Bashan, Jun2019 에 임명되었습니다 의 임기는 6.92 년입니다. 총 연간 보상은 $1.17M, 34.4% 급여 및 65.6% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $5.34M 가치에 해당하는 회사 주식의 3.14% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.3 년과 6.3 년입니다.
핵심 정보
Dror Bashan
최고경영자
US$1.2m
총 보수
| CEO 급여 비율 | 34.44% |
| CEO 재임 기간 | 6.9yrs |
| CEO 지분 보유율 | 3.1% |
| 경영진 평균 재임 기간 | 5.3yrs |
| 이사회 평균 재임 기간 | 6.3yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 11
PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).내러티브 업데이트 • Apr 26
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts now set Protalix BioTherapeutics' price target at $11.00. The unchanged level reflects only minimal tweaks to inputs such as the discount rate, long term revenue growth, profit margin assumptions and future P/E expectations.내러티브 업데이트 • Apr 09
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have maintained their $11.00 price target for Protalix BioTherapeutics, citing relatively stable assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the basis for keeping their outlook unchanged. What's in the News The European Commission approves a 2 mg/kg every four weeks dosing regimen for pegunigalsidase alfa in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every two weeks to every four weeks (Key Developments).내러티브 업데이트 • Mar 26
PLX: New Dosing Approval And 2026 Outlook Will Support Undervalued Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, highlighting revised assumptions for revenue growth, profit margins, the discount rate and future P/E as key drivers behind their updated model. What's in the News Protalix BioTherapeutics issued 2026 total revenue guidance of approximately $78.0 million to $83.0 million, which includes a $25.0 million milestone payment from Chiesi tied to regulatory progress for Elfabrio (company guidance).내러티브 업데이트 • Mar 09
PLX: Extended Fabry Dosing Will Support Undervalued Long Term Outlook
Analysts have reiterated an $11.00 price target for Protalix BioTherapeutics, citing only slight tweaks to model inputs such as the discount rate, long-term revenue growth, profit margins, and future P/E assumptions rather than any major shift in their overall view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the European Medicines Agency's Committee for Medicinal Product for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy (Key Developments).내러티브 업데이트 • Feb 23
PLX: Fabry Dosing Extension Will Support Undervalued Long Term Outlook
Analysts are maintaining their $11.00 price target for Protalix BioTherapeutics while slightly refining core modeling inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions to better align with their updated risk and earnings outlook. What's in the News CHMP of the EMA issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa in adult Fabry disease patients who are stable on enzyme replacement therapy, potentially giving eligible patients a longer interval between infusions (Product related announcement).내러티브 업데이트 • Feb 08
PLX: Renal ASO Pipeline And Fabry Dosing Expansion Will Drive Upside
Analysts have maintained their price target for Protalix BioTherapeutics at US$11.00, citing a combination of updated assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple as reasons to keep their existing valuation view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy, aiming to extend time between infusions so patients can focus more on daily life (Key Developments).내러티브 업데이트 • Jan 24
PLX: Renal ASO Collaboration Will Drive Next Phase Of Upside Potential
Analysts have maintained their US$11.00 price target for Protalix BioTherapeutics, citing only slight adjustments to their discount rate, long term revenue growth, profit margin assumptions and future P/E outlook, rather than any major shift in their thesis. What's in the News Protalix BioTherapeutics and Secarna Pharmaceuticals entered a collaboration and option agreement to discover antisense oligonucleotide therapies targeting rare renal indications, with Secarna using its OligoCreator platform to design and profile candidates and Protalix selecting the biological targets (Key Developments).내러티브 업데이트 • Jan 10
PLX: Renal Collaboration Agreement Will Drive Next Phase Of Upside Potential
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at US$11.00. This reflects only minor adjustments to assumptions around discount rate, revenue growth, profit margins and future P/E that do not materially change their overall view.내러티브 업데이트 • Dec 16
PLX: European Label Expansion Review Will Drive Next Phase Of Upside Potential
Analysts have nudged their price target on Protalix BioTherapeutics slightly higher to $11.00, reflecting marginal adjustments to discount rate, long term growth, and profitability assumptions, while maintaining a broadly consistent valuation framework. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics requested re examination of the EMA CHMP negative opinion on adding a once every 4 weeks 2 mg/kg Elfabrio dosing regimen to the currently approved every 2 weeks regimen, seeking broader label flexibility in Europe (Key Developments) Safety data from Elfabrio clinical trials highlighted hypersensitivity reactions in 14 percent of treated patients and anaphylaxis in 3 percent, underscoring the need for careful infusion monitoring and potential dose adjustments (Key Developments) Additional clinical observations included infusion associated reactions in 29 percent of Elfabrio patients and a reported case of membranoproliferative glomerulonephritis, prompting recommendations to monitor renal function and infusion related symptoms (Key Developments) Protalix BioTherapeutics was added to the S&P Global BMI Index, potentially increasing its visibility and accessibility to global institutional investors (Key Developments) Valuation Changes Fair value estimate maintained at $11.00 per share, indicating no change to the analyst target price.내러티브 업데이트 • Dec 02
PLX: European Regulatory Review Will Unlock Next Phase Of Upside Potential
Analysts have lowered their price target for Protalix BioTherapeutics from $12.50 to $11.00, citing a slight reduction in expected revenue growth and profit margins. What's in the News Protalix BioTherapeutics and Chiesi Global Rare Diseases have requested a re-examination of the negative opinion by the European Medicines Agency regarding the new dosing regimen for Elfabrio.내러티브 업데이트 • Nov 18
PLX: European Review Process Will Drive Next Phase Of Momentum
Analysts have lowered their price target for Protalix BioTherapeutics from $14.00 to $12.50. They cite more conservative expectations regarding revenue growth and profit margins.
새로운 내러티브 • May 19
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on
새로운 내러티브 • Apr 29
PRX-115 Trials And Elfabrio Launch Will Open Future Markets
Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption.분석 기사 • Feb 22
Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon
We feel now is a pretty good time to analyse Protalix BioTherapeutics, Inc.'s ( NYSEMKT:PLX ) business as it appears...분석 기사 • Jan 14
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...분석 기사 • Dec 10
Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Protalix BioTherapeutics, Inc. ( NYSEMKT:PLX ) can tell us which group is most powerful...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$15m |
| Dec 31 2025 | US$1m | US$402k | -US$7m |
| Sep 30 2025 | n/a | n/a | US$5m |
| Jun 30 2025 | n/a | n/a | US$6m |
| Mar 31 2025 | n/a | n/a | US$4m |
| Dec 31 2024 | US$2m | US$374k | US$3m |
| Sep 30 2024 | n/a | n/a | -US$10m |
| Jun 30 2024 | n/a | n/a | -US$15m |
| Mar 31 2024 | n/a | n/a | US$7m |
| Dec 31 2023 | US$3m | US$357k | US$8m |
| Sep 30 2023 | n/a | n/a | US$11m |
| Jun 30 2023 | n/a | n/a | US$9m |
| Mar 31 2023 | n/a | n/a | -US$16m |
| Dec 31 2022 | US$1m | US$360k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$18m |
| Jun 30 2022 | n/a | n/a | -US$18m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$1m | US$374k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$21m |
| Jun 30 2021 | n/a | n/a | -US$21m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$1m | US$352k | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$9m |
| Dec 31 2019 | US$566k | US$175k | -US$18m |
보상 대 시장: Dror의 총 보수(USD1.17M)는 US 시장에서 비슷한 규모 기업의 평균(USD1.59M) 수준입니다.
보상과 수익: Dror의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Dror Bashan (58 yo)
6.9yrs
재임 기간
US$1,166,934
보수
Mr. Dror Bashan has been President, Chief Executive Officer and Director of Protalix BioTherapeutics, Inc. since June 30, 2019. He has experience in the pharmaceutical industry with roles ranging from busi...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 6.9yrs | US$1.17m | 3.14% $ 5.3m | |
| Senior VP | less than a year | US$539.14k | 0.0045% $ 7.7k | |
| SVP & COO | 8yrs | US$575.77k | 0.29% $ 490.1k | |
| Vice President of Human Resources | 3.8yrs | 데이터 없음 | 데이터 없음 |
5.3yrs
평균 재임 기간
58yo
평균 나이
경험이 풍부한 관리: PLX의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 6.9yrs | US$1.17m | 3.14% $ 5.3m | |
| Independent Director | 17.8yrs | US$71.71k | 0.0093% $ 15.8k | |
| Independent Director | 11.5yrs | US$71.71k | 0.39% $ 655.2k | |
| Independent Director | 6.3yrs | US$71.71k | 0.0093% $ 15.8k | |
| Member of Scientific Advisory Board | 9.9yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.9yrs | US$71.34k | 0.0093% $ 15.8k | |
| Chairman of Scientific Advisory Board | no data | US$55.00k | 데이터 없음 | |
| Independent Chairman | 2.7yrs | US$99.58k | 0.0093% $ 15.8k | |
| Independent Director | 6.3yrs | US$71.71k | 0.0094% $ 15.9k | |
| Director | less than a year | US$20.08k | 0.0093% $ 15.8k |
6.3yrs
평균 재임 기간
72yo
평균 나이
경험이 풍부한 이사회: PLX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.3 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/31 23:01 |
| 종가 | 2026/05/29 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Protalix BioTherapeutics, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Peter Welford | Jefferies LLC |